GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHF) » Definitions » Days Payable

Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Days Payable : 140.68 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Days Payable?

Sihuan Pharmaceutical Holdings Group's average Accounts Payable for the six months ended in Dec. 2023 was $27.7 Mil. Sihuan Pharmaceutical Holdings Group's Cost of Goods Sold for the six months ended in Dec. 2023 was $36.0 Mil. Hence, Sihuan Pharmaceutical Holdings Group's Days Payable for the six months ended in Dec. 2023 was 140.68.

The historical rank and industry rank for Sihuan Pharmaceutical Holdings Group's Days Payable or its related term are showing as below:

SHPHF' s Days Payable Range Over the Past 10 Years
Min: 13.54   Med: 29.6   Max: 137.38
Current: 130.68

During the past 13 years, Sihuan Pharmaceutical Holdings Group's highest Days Payable was 137.38. The lowest was 13.54. And the median was 29.60.

SHPHF's Days Payable is ranked better than
69.82% of 974 companies
in the Drug Manufacturers industry
Industry Median: 88.68 vs SHPHF: 130.68

Sihuan Pharmaceutical Holdings Group's Days Payable declined from Dec. 2022 (148.83) to Dec. 2023 (140.68). It may suggest that Sihuan Pharmaceutical Holdings Group accelerated paying its suppliers.


Sihuan Pharmaceutical Holdings Group Days Payable Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Days Payable Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.11 55.59 66.75 88.39 137.60

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 131.67 57.95 148.83 116.41 140.68

Competitive Comparison of Sihuan Pharmaceutical Holdings Group's Days Payable

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sihuan Pharmaceutical Holdings Group's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Days Payable distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Days Payable falls into.



Sihuan Pharmaceutical Holdings Group Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Sihuan Pharmaceutical Holdings Group's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

Days Payable (A: Dec. 2023 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2022 ) + Accounts Payable (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (29.517 + 30.132) / 2 ) / 79.114*365
=29.8245 / 79.114*365
=137.60

Sihuan Pharmaceutical Holdings Group's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

Days Payable (Q: Dec. 2023 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jun. 2023 ) + Accounts Payable (Q: Dec. 2023 )) / count ) / Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=( (25.342 + 30.132) / 2 ) / 35.983*365 / 2
=27.737 / 35.983*365 / 2
=140.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sihuan Pharmaceutical Holdings Group Days Payable Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Business Description

Traded in Other Exchanges
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.